Welcome to our dedicated page for PPD news (Ticker: PPD), a resource for investors and traders seeking the latest updates and insights on PPD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PPD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PPD's position in the market.
PPD, a global contract research organization, is expanding its GMP laboratory in Athlone, Ireland. The facility will increase from 4,460 sq. meters to 7,710 sq. meters, enhancing capabilities in biopharmaceutical testing, especially for cell and gene therapies. The project aims to meet rising customer demand in Europe, the Middle East, and Asia-Pacific, creating 180 jobs in three years. Completion is expected by mid-2022. The expansion supports PPD's commitment to delivering integrated drug development services and improving time-to-market for new therapies.
PPD, a global contract research organization, reported strong Q1 2021 results with a 28.5% revenue increase to $1,378.4 million and 39.3% growth in net authorizations, amounting to $1,481.6 million. Net income reached $74.5 million, up from $4.2 million a year prior. Adjusted EBITDA stood at $240.9 million. Backlog rose 18.7% to $8,682.5 million. Following the announcement of a merger with Thermo Fisher, PPD will no longer provide financial guidance.
PPD, a global contract research organization, announced a collaboration with Science 37 to enhance decentralized clinical trials using Science 37's DCT SaaS-based technology platform. This partnership aims to optimize clinical trial solutions, allowing for Remote eConsent and improved patient engagement while reducing site reliance. PPD has been recognized by ISG for its leadership in digital trial solutions. The collaboration builds on a successful two-year partnership, aiming to streamline trial delivery, increase patient access, and accelerate drug development timelines.
Thermo Fisher Scientific has announced its acquisition of PPD for $47.50 per share, totaling $17.4 billion plus $3.5 billion in net debt. This deal represents a 24% premium to PPD's stock price as of April 13, 2021. PPD, a leader in the $50 billion clinical research services industry, generated $4.7 billion in revenue in 2020. The transaction is expected to close by the end of 2021 and will enhance Thermo Fisher's services to the pharma and biotech sectors, with projected cost synergies of $125 million by year three.
PPD will host a conference call on April 28, 2021, at 8 a.m. ET to discuss its Q1 2021 financial results. Investors can join the call via a live webcast available on PPD’s investor website or by phone. The call can be accessed at +1 877 407 0784 (domestic) or +1 201 689 8560 (international) with a replay available until May 12, 2021. PPD is a leading global contract research organization that offers comprehensive drug development and lifecycle management services, employing over 26,000 professionals across 47 countries.
PPD and Clinical Ink have partnered to streamline clinical trials for systemic lupus erythematosus (SLE). Their collaboration leverages a tailored version of Clinical Ink's electronic Lupus Assessment Suite (eLAS) to improve data quality and operational efficiency. This initiative allows for near real-time access to SLE endpoint data, addressing challenges related to placebo response variability. PPD’s team, which includes SLE experts, will enhance the accuracy of trial results while ensuring quick data validation. This innovation aims to support pharmaceutical clients in developing new SLE treatments.
PPD has been recognized as a leader in digital and decentralized clinical trial solutions by Information Services Group (ISG) in its 2020 Provider Lens report. The recognition highlights PPD's strengths in clinical development and patient engagement, showcasing its ability to enhance patient experience through innovative digital solutions. PPD's flexible protocols address the needs of patients while mitigating risks in research. The company secured over 60 awards in 2020 across various therapeutic areas, reflecting its commitment to improving clinical trial accessibility and efficiency.
PPD is participating in Rare Disease Day on February 26, 2021, to raise awareness about rare diseases. The company will illuminate its headquarters in Wilmington, NC, with colors representing rare diseases. This event reflects PPD's commitment to drug research in this area and its dedication to improving the lives of affected patients. The illumination will begin shortly after dusk and will last until 11:30 p.m. PPD emphasizes its ongoing efforts in rare disease research and the importance of educating the public on these conditions.
PPD, a global contract research organization, will virtually present at the Barclays Global Healthcare Conference on March 9, 2021, at 3:35 p.m. ET. CEO David Simmons and CFO Chris Scully will participate in a fireside chat. Investors can access the live presentation on PPD’s investor relations website, with an archived version available for 30 days post-event. PPD operates in 46 countries, employing over 26,000 professionals, and offers integrated drug development services to various sectors, including pharmaceutical and biotechnology companies.
PPD, Inc. (Nasdaq: PPD) reported robust financial results for Q4 and the full year 2020. Q4 net authorizations reached $1,297.6 million, up 28.1%, with a net book-to-bill ratio of 1.30x. FY 2020 net authorizations totaled $4,613.7 million, reflecting 20.5% growth. Revenue for Q4 was $1,364.3 million (up 30.3%), and for FY 2020, $4,681.5 million (up 16.1%). Net income rose significantly, with Q4 net income of $73.1 million (up 980.2%). For 2021, PPD anticipates revenues between $5,145 million and $5,304 million.
